Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study

Grant D Stewart, Leander Van Neste, Philippe Delvenne, Paul Delrée, Agnès Delga, S Alan McNeill, Marie O'Donnell, James Clark, Wim Van Criekinge, Joseph Bigley, David J Harrison

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Concern about possible false-negative prostate biopsy histopathology findings often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay panel, including GSTP1, APC and RASSF1, could increase the sensitivity of detecting cancer over that of pathological review alone, leading to a high negative predictive value and a decrease in unnecessary repeat biopsies.
Original languageEnglish
Pages (from-to)1110-1116
Number of pages7
JournalThe Journal of urology
Volume189
Issue number3
DOIs
Publication statusPublished - 2013

Keywords / Materials (for Non-textual outputs)

  • prostate
  • prostatic neoplasms
  • biopsy
  • epigenomics

Fingerprint

Dive into the research topics of 'Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study'. Together they form a unique fingerprint.

Cite this